Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
C9JLJ4

UPID:
U17LD_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
C9JLJ4

BACKGROUND:
The Ubiquitin carboxyl-terminal hydrolase 17-like protein 13 is a critical enzyme in the ubiquitin-proteasome system, responsible for the removal of ubiquitin from substrate proteins. This action is essential for various cellular functions, including proliferation, apoptosis, and migration, as well as the immune response to viral pathogens. The enzyme's specificity and regulatory roles underscore its importance in cellular physiology and stress responses.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ubiquitin carboxyl-terminal hydrolase 17-like protein 13 holds promise for identifying novel therapeutic targets. Given its central role in managing cell cycle, apoptosis, and immune responses, targeting this protein could lead to breakthroughs in treating diseases with underlying cellular dysfunctions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.